Australian universities are pressing the federal government to approve two Chinese vaccines Sinovac and Sinopharm, after Australia’s drug regulator, the Therapeutic Goods Administration (TGA), said it would soon advise the government on Chinese and Indian vaccines.
The regulator has so far approved Pfizer, Johnson & Johnson, Moderna and AstraZeneca.
Citing the recognition of Chinese vaccines by the World Health Organization (WHO) and that the United States, the United Kingdom, and Canada have already decided to admit Chinese students, the university sector urged the government to move quickly on the issue. is requesting.
“We are encouraging the Commonwealth to move quickly on that,” Professor Barney Glover, coordinator of the NSW Chancellor’s Committee, told the Sydney Morning Herald. “It’s not just important for international education. It’s going to be important for short visits and long visits.”
Glover’s remarks came after the New South Wales (NSW) state government confirmed last week that hundreds of vaccinated international students would return to the state by 2022.
However, Chinese students are unlikely to participate in the pilot program of a major market if they are vaccinated with Sinovac or SinoPharm, which have not been approved by the TGA.
Concerns have long been raised about the effectiveness of Chinese vaccines, with both Thailand and Indonesia reporting fully vaccinated with Sinovac to healthcare workers who are still infected with the CCP virus.
Brazil on September 4 also suspended the use of more than 12 million doses of Chinese-made vaccines over concerns over the vaccine’s efficacy.
The WHO has approved the emergency use of two Chinese vaccines: CoronaVac made by Sinovac and BIBP made by Sinopharm/China National Pharmaceutical Group. However, a staff member of China’s CDC system revealed that the data provided by Beijing to the WHO was misrepresented.
The staff member also noted that the actual rate of adverse reactions was much higher than what was officially announced.
Actual data on adverse reactions and deaths related to Chinese vaccines has been of concern to the international community since Hong Kong stopped releasing part of its vaccine-related death figures in June.
The data was being used by the public to estimate the total number of deaths due to Chinese vaccines in mainland China.
Professor John Skerritt, head of the TGA, said one of the biggest challenges for the regulator is that Chinese and Indian vaccines do not have as much transparent information in the medical literature and publicly available reports as accepted in Europe, North America and Australia. Vaccines have it.
Skerritt said more advisories would be announced when the regulator receives new information.
“But we’re also going to those governments and trying to get information … that’s also available, but not public, on those vaccines,” he told NCA Newswire.
This News Originally From – The Epoch Times